Provided by Tiger Fintech (Singapore) Pte. Ltd.

vTv Therapeutics

16.31
-0.3567-2.14%
Post-market: 16.310.00000.00%16:04 EDT
Volume:2.84K
Turnover:46.50K
Market Cap:42.70M
PE:-2.28
High:16.31
Open:16.31
Low:16.31
Close:16.67
Loading ...

vTv Therapeutics Inc. Files Initial Statement of Beneficial Ownership for EVP & CFO Michael Stephen Tung

Reuters
·
22 May

vTv Therapeutics Appoints New CFO Amidst Phase 3 Trial

TIPRANKS
·
20 May

vTv Therapeutics Reinitiates Phase 3 Trial for Cadisegliatin, a Promising Oral Adjunctive Therapy for Type 1 Diabetes

Reuters
·
20 May

vTv Therapeutics Names Michael Tung as Finance Chief

MT Newswires Live
·
19 May

vTv Therapeutics appoints Tung as CFO

TIPRANKS
·
19 May

vTv Therapeutics Appoints Michael Tung, M.d., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1d Adjunctive Therapy to Insulin

THOMSON REUTERS
·
19 May

Press Release: vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

Dow Jones
·
19 May

Buy Rating for vTv Therapeutics: Promising Potential of Cadisegliatin in Type 1 Diabetes Treatment

TIPRANKS
·
16 May

vTv Therapeutics Q1 EPS $(0.77) Beats $(0.92) Estimate

Benzinga
·
16 May

vTv Therapeutics Inc - Topline Phase 3 Data for Cadisegliatin Expected in 2H 2026

THOMSON REUTERS
·
16 May

BRIEF-VTV Therapeutics Announces Reinitiation Of Screening In CATT1 Phase 3 Trial

Reuters
·
16 May

Sector Update: Health Care Stocks Higher Thursday Afternoon

MT Newswires Live
·
16 May

vTv Therapeutics Resumes Cadisegliatin Testing in Type 1 Diabetes

MT Newswires Live
·
16 May

vTv Therapeutics Announces Reinitiation of Screening in Catt1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

THOMSON REUTERS
·
16 May

vTv Therapeutics Inc - Protocol Amendment Shortens Trial Duration to 6 Months

THOMSON REUTERS
·
16 May

vTv Therapeutics Inc - Topline Catt1 Phase 3 Data Expected in 2H 2026

THOMSON REUTERS
·
16 May

vTv Therapeutics Inc expected to post a loss of 81 cents a share - Earnings Preview

Reuters
·
05 May

HC Wainwright Initiates vTv Therapeutics With Buy Rating, $36 Price Target

MT Newswires Live
·
09 Apr

BUZZ-H.C. Wainwright starts vTv Therapeutics with 'buy' as diabetes drug study set to resume

Reuters
·
09 Apr

vTv Therapeutics Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
09 Apr